Pyxis Oncology (PYXS) to Announce Quarterly Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $0.0330 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 20, 2026 at 12:30 PM ET.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). On average, analysts expect Pyxis Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pyxis Oncology Trading Up 2.7%

Shares of Pyxis Oncology stock opened at $3.83 on Tuesday. The firm has a market capitalization of $242.63 million, a PE ratio of -2.92 and a beta of 1.31. The firm’s 50 day moving average is $2.45 and its 200 day moving average is $1.94. Pyxis Oncology has a 1 year low of $0.97 and a 1 year high of $5.55.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently made changes to their positions in PYXS. Maia Wealth LLC acquired a new position in shares of Pyxis Oncology in the fourth quarter worth approximately $25,000. Engineers Gate Manager LP acquired a new stake in Pyxis Oncology during the 4th quarter valued at approximately $26,000. Fox Run Management L.L.C. acquired a new stake in Pyxis Oncology during the 4th quarter valued at approximately $26,000. XTX Topco Ltd bought a new position in Pyxis Oncology during the 2nd quarter worth approximately $40,000. Finally, LPL Financial LLC raised its holdings in Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after purchasing an additional 21,100 shares during the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wedbush initiated coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 target price on the stock. Leerink Partners dropped their price target on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, July 2nd. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wells Fargo & Company assumed coverage on Pyxis Oncology in a research report on Monday, August 3rd. They set an “overweight” rating and a $12.00 price objective on the stock. Finally, Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.